Epithalon

What is Epithalon?

Epithalon and Epitalon usually refer to the same four-amino-acid peptide, H-Ala-Glu-Asp-Gly-OH. FDA uses “Epitalon” and recognizes “Epithalon” as an alternate name. Because neither is a formal USAN, research records should include sequence, molecular form, counterion, and assay basis.

Free base (C14H22N4O9, ≈390.35 g/mol, CAS 307297-39-8) and acetate (represented 1:1 ≈450.40 g/mol, CAS 307297-40-1) are not interchangeable without assay conversion. A vial labeled only “Epithalon 10 mg” does not disclose what 10 mg means.

Epitalon and Epithalamin are not interchangeable

Epithalamin is an animal-tissue extract containing a mixture of pineal peptides. Epitalon is one synthetic tetrapeptide developed from study of that extract. Similar names do not make milligram doses equivalent.

The frequently cited 2003 study that followed 266 older adults evaluated Thymalin and Epithalamin, alone or together — not synthetic AEDG. Its mortality findings cannot establish an Epitalon dose or longevity effect.

What has actually been studied in humans?

FDA’s 2026 literature review identified three publications administering synthetic Epitalon/AEDG to humans: two sublingual circadian-biomarker publications (likely related/overlapping) and one parabulbar retinitis-pigmentosa report.

There is no FDA-approved dosage. The exposures below are research exposures — not a prescribing protocol.

A biomarker increase in urinary 6-SMT is not proof of insomnia treatment. Parabulbar injection is an ophthalmic procedure — never a self-administered systemic route.

Epitalon research dosage range

Direct human evidence supports only two very different exposures: 0.5 mg/day SL × 20 days and 5 µg/eye × 10 days. It does not support a general 5–10 mg subcutaneous cycle.

The common 5–10 mg amount is 10–20× the 0.5 mg/day human SL exposure and roughly 17–100× the 100–300 µg translational range. These are administered-mass comparisons — not exposure equivalence (bioavailability unknown).

The 2026 microgram-dose hypothesis

A 2026 mini-review proposed that future human dose-finding begin around 100–300 µg per treatment day, highlighting the Epithalamin-to-Epitalon dosing error. Inputs included ≈500-fold potency contrast in one primate melatonin model, long-term mouse work at 1 µg/mouse, and a surface-area HED of roughly 2.7–3.3 µg/kg.

This remains a single-author hypothesis, not a human trial. Route, frequency, and course length are undefined. Body-surface-area scaling is weak without PK. The table below is mathematical only — not individualized dosing.

Protocol A: 20-day sublingual replication study

The most defensible fixed protocol replicates the published human sublingual exposure — preserving route and daily mass rather than converting it into an injection schedule.

Active: 0.25 mg SL twice daily × 20 days (0.5 mg/day; 10 mg cumulative). Placebo-controlled, no escalation, no catch-up, 28-day follow-up, no automatic repeat cycle.

Primary PD endpoint: overnight urinary 6-SMT change. Key clinical sleep endpoint should be actigraphy-derived TST/efficiency or a validated insomnia measure — do not declare “circadian restoration” from one urine sample.

Protocol B: exploratory 0.2 mg SC sentinel cohort

No human SC dose has been established. A formal dose-finding pilot concept uses 0.2 mg (200 µg) SC once daily × 10 days (cumulative 2.0 mg) with placebo control, PK sampling, and independent safety review — approximating the 70 kg HED band from the 2026 review.

Prefer a purpose-made 0.2 mg single-dose presentation. Do not improvise from an unidentified high-mass vial. This does not replace Protocol A and is not a treatment schedule. No evidence-based SC escalation ladder exists.

Reconstitution and concentration math

Reconstitution math shows volume — not solubility, sterility, stability, or suitability for injection. FDA’s 2026 review found limited aqueous-solubility data and noted free-base injection may be difficult to prepare at ~3 mg/mL in water.

For Protocol B, cleanest math uses a 0.2 mg single-dose vial (e.g., 0.20 mL at 1.0 mg/mL = 20 U-100 volume units). A 10 mg community vial is poorly suited to a 0.2 mg research question.

The highest common legacy cycle cumulative mass is 100× the proposed 2 mg SC pilot. No human study establishes that larger cumulative exposure is more effective or acceptably safe. U-100 “units” are volume markings only.

Preclinical research dosages

Long-term SHR mice received 1 µg/mouse SC on 5 consecutive days each month. Epitalon did not significantly change mean lifespan; maximum lifespan reportedly increased ~12%, with model-specific tumor findings. Rhesus work used ~10 µg/animal/day IM × 10 days for melatonin/cortisol rhythms.

Animal and cell exposures are not human dosage instructions. Cultured-cell telomere/telomerase findings (including 2025 ALT activity in some cancer lines) do not prove human longevity benefit or cancer safety.

Mechanisms under investigation

Telomerase / telomeres: cell-culture work reports hTERT/telomerase upregulation and telomere lengthening; 2025 work also found ALT-associated extension in some breast-cancer lines — a reason for uncertainty, not a cancer-treatment claim.

Circadian / pineal: old macaques showed melatonin/cortisol rhythm effects; human SL study increased urinary 6-SMT. Isolated rat pineal superfusion did not show direct acute melatonin release at 1–100 µM.

Gene-expression / epigenetic hypotheses and antioxidant/retinal/immune findings remain mechanistic and often network-concentrated.

Expected results and timeline

Subjective vivid dreams, energy, or “recovery” need blinded comparison — expectancy and concurrent supplements confound pre/post reports.

Safety and adverse effects

Human safety reporting is inadequate. FDA found no clinical study designed to assess Epitalon safety, particularly by the SC route. No formal MTD, human SC PK/immunogenicity, established AE incidence, or validated repeat-cycle safety.

Telomerase activation is not automatically beneficial. Conservative research excludes active/recent cancer and unexplained masses unless oncology-directed.

Route of administration

Storage and stability

FDA cited lyophilized free-base stability ~3 weeks at room temperature, with longer-term storage desiccated below −18°C, and reconstituted free-base roughly 2–7 days at 4°C — not a universal finished-product label. Do not infer a 28-day refrigerated period from bacteriostatic water alone.

Use lot-specific stability data, prefer single-dose presentations, and discard after unsupported excursions, appearance changes, or missing identity/volume/date records.

Combining Epitalon with other peptides

No controlled study has established safety, dose, or synergy with GH secretagogues, thymic peptides, BPC-157, TB-500, GHK-Cu, NAD-related interventions, exosomes, or plasma exchange. Factorial arms are required — not a pre/post “stack” comparison.

U.S. status as of August 2026

There is no U.S. prescribing label. FDA evaluated Epitalon free base and acetate for compounded insomnia use at the July 2026 PCAC meeting. Staff recommended against 503A Bulks List inclusion; the advisory committee then voted narrowly in favor of recommending inclusion.

The committee vote is nonbinding and is not drug approval or an efficacy finding. Final list change requires FDA action.

Common claims vs evidence

Dosage evidence ladder

Epitalon dosing is poorly established. A small human study provides a reproducible 0.5 mg/day SL research exposure, but no study defines a systemic injection dose, dose-response curve, MTD, or repeat interval.

WADA and tested sport

Epitalon/Epithalon was not found by name on the 2026 WADA Prohibited List. WADA S0 prohibits pharmacological substances lacking current governmental therapeutic approval. Tested athletes should treat Epitalon as likely prohibited under S0 unless their authority provides a current written determination.

Bottom line

Epithalon/Epitalon is a defined AEDG tetrapeptide with intriguing cell and animal research, but human dosing evidence is narrow. The clearest systemic human exposure is 0.5 mg/day SL × 20 days; the other traceable human dose is local 5 µg/eye. Neither validates community subcutaneous use.

The familiar 5–10 mg injection cycle appears to inherit Epithalamin extract dosing. A 2026 review proposed formal dose-finding around 100–300 µg/treatment day, but that remains indirect. A defensible program first replicates the SL study and, if evaluating SC, uses a monitored microgram-range sentinel cohort with PK, placebo, qualified single-dose material, and no automatic repeat cycle.

Confirm AEDG identity (≠ Epithalamin), free base vs acetate assay, and do not treat legacy milligram injection cycles as synthetic-Epitalon evidence.

Frequently asked questions

References

• FDA

  Epitalon-Related Bulk Drug Substances: July 2026 PCAC evaluation

  FDA briefing document.

• Ivko OM et al.

  AEDG peptide regulation of human circadian rhythm genes

  Adv Gerontol 2021 — 0.5 mg/day SL × 20 days biomarker study.

• Khavinson V et al.

  Epitalon improves eye retina condition in retinitis pigmentosa

  Neuro Endocrinol Lett 2002 — 5 µg/eye parabulbar context.

• Jung CH

  The microgram hypothesis: translational dosing error in Epitalon research

  Aging Pathobiol Ther 2026 — 100–300 µg/day hypothesis.

• Anisimov VN et al.

  Epitalon on biomarkers of aging and lifespan in SHR mice

  Biogerontology 2003 — 1 µg/mouse monthly courses.

• Al-Dulaimi S et al.

  Epitalon increases telomere length in human cell lines

  Biogerontology 2025 — telomerase and ALT findings.

• Khavinson VKh, Morozov VG

  Peptides of pineal gland and thymus prolong human life

  2003 — Epithalamin ± Thymalin, not synthetic Epitalon.

• WADA

  2026 Prohibited List

  Not named individually; S0 likely relevant.